DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20195506

Immunohistochemical expression of human epididymis 4 in ovarian malignancy

Begum Afrin Nahar, Rama Saha, Chhanda Das, Gourishankar Kamilya

Abstract


Background: Ovarian malignancies has the highest mortality rate among all gynaecological malignancies. Surface epithelial tumors form two thirds of all ovarian neoplasm and 90% of all ovarian cancers are surface epithelial carcinomas. Mortality in case of ovarian malignancy is high due to late diagnosis. Early and accurate diagnosis can improve the case specific management. HE4 (Human Epididymis Protein 4) which is proved to be overexpressed in the ovarian cancer cells, is considered a new biomarker for ovarian cancer diagnosis which helps in early diagnosis and patient management. Aims and objectives of the study was to evaluate the immunohistochemical expression of HE4 in various ovarian malignancies.

Methods: It was a cross sectional, prospective, single institution-based study, conducted in the department of Pathology in collaboration with the Department of Gynaecology and Obstetrics, from December 2016 to January 2019 in institution. A total 74 ovarian malignancies were selected for this study.

Results: Serous carcinoma was the most common ovarian malignancy followed by endometrioid carcinoma. Highest percentage of expression of HE4 was seen in high grade serous cancer and malignant endometrioid tumor.

Conclusions: HE4 was highly expressed in malignant ovarian tumour especially serous and endometrioid carcinoma and can be used as an important biomarker for malignant ovarian neoplasm. Expression in high grade ovarian serous cancer support its prognostic value also.


Keywords


Biomarker, Immunohistochemical, Human epididymis protein 4, Ovarian malignancy

Full Text:

PDF

References


Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clini Oncol. 2012 Feb 6;30(8):880-7.

Dawar R. Surface epithelial tumours of the ovary. Indian J Medi Paediatr Oncol. 2004 Apr 1;25(1):5-9.

Nolen B, Marrangoni A, Velikokhatnaya L, Prosser D, Winans M, Gorelik E, et al. A serum-based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol. 2009 Jan 1;112(1):47-54.

Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Repro. 1991 Aug 1;45(2):350-7.

Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005 Mar 15;65(6):2162-9.

Chen X, Zhou H, Chen R, He J, Wang Y, Huang L, et al. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Clini Chimica Acta. 2015 Feb 2;440:57-63.

Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 2010 Apr 1;31(2):113-9.

Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003 Jul 1;63(13):3695-700.

Bulut T, Celik B, Yalcin AD, Keser S. Tissue expression of HE4 and its correlation with CA125 and P53 in high grade serous ovarian carcinoma. Eur J Gynaecol Oncol. 2017 Jan 1;38:745-9.

Bouchard D, MorissetD,Bourbonnais Y, Tremblay GM(2006) Proteinswith whey-acidic-protein motifs and cancer. Lancet Oncol 7: 167-174.

Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009 Jan 1;112(1):40-6.

Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. The utility of serum human epididymis protein 4 (HE4) in patients with malignant and non-malignant diseases: comparison with CA125. Clin Chem. 2011;57(11):1534-44.

Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005 Mar 15;65(6):2162-9.

Jha R, Karki S. Histological pattern of ovarian tumors and their age distribution. Nepal Med Coll J. 2008 Jun;10(2):81-5.

Maheshwari V, Tyagi SP, Saxena K, Tyagi N, Sharma R, Aziz M, et al. Surface epithelial tumours of the ovary. Indi J Pathol Microbio. 1994 Jan;37(1):75-85.

Husaini HA, Soudy H, Darwish AE, Ahmed M, Eltigani A, Mubarak MA, et al. Pure dysgerminoma of the ovary: a single institutional experience of 65 patients. Medi Oncol. 2012 Dec 1;29(4):2944-8.

Devan SM, Pailoor J, Sthaneshwar P, Narayanan V. Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels. Asian Paci J Cancer Pre. 2013;14(8):4545-8.

Rahmat F, Ithnin H. Immunohistochemical Expression of Human Epididymis 4 (He4) in Ovarian Serous Carcinoma in Hospital Serdang from the Year 2006-2013. Gynecol Obstet. 2017;7(453):2161-0932.

Georgakopoulos P, Mehmood S, Akalin A, Shroyer KR. Immunohistochemical localization of HE4 in benign, borderline, and malignant lesions of the ovary. Int J Gynecol Pathol. 2012 Nov 1;31(6):517-23.

Zheng LE, Qu JY, He F. The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer. Open Medi. 2016 Jan 1;11(1):125-32.